Final Program

MONDAY • MAY 16 139
9:00 Improving Sleep in Athletes: An Overlooked and
Underutilized Training Method
B. Marcello, PhD, Carlsbad, CA
9:15 Sleep and Circadian Misalignment in Athletes
S. Halson, PhD, Belconnen, Australia
9:35 Athletes Sleeping/Training in Hypoxia: Good Idea or Bad?
J. Dempsey, PhD, Madison, WI
9:55 Sleep, Health, and Performance in Student Athletes
M. Grandner, PhD, Tucson, AZ
10:15 Sleep Apnea Risk, Diagnosis and Treatment in Professional
Football
I. Gurubhagavatula, MD, MPH, Philadelphia, PA
10:45 Sleep Disorders in Athletes: A Player's Perspective
A. Taylor, San Diego, CA
B9
CLINICAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
SICKLE CELL DISEASE AND THE LUNG ACROSS
THE LIFESPAN
Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical
Problems; Pulmonary Circulation; Sleep and Respiratory Neurobiology
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3007/3009 (West Building, Level 3)
Target Audience
Pediatric and adult pulmonary fellows, clinicians and researchers interested in
the pulmonary complications of sickle cell disease (SCD) across the lifespan.
Objectives
At the conclusion of this session, the participant will be able to:
• gain an understanding of the burden of SCD around the globe and the
importance of newborn screening and early intervention in the context of
early SCD mortality in resource-poor settings;
• review the state of evidence-based management of pulmonary
complications of SCD with emphasis on current guidelines as well as areas
where evidence is lacking;
• understand the impact of abnormalities throughout the respiratory system
(airway, gas exchange, and vascular) as disease modulators in the long
term pathogenesis of SCD throughout the lifespan.
Despite a high and growing global burden of SCD with an estimated 400,000
births per year by 2050, evidence-based interventions against its pulmonary
complications are limited. Pulmonary complications are among the most
common causes of the observed accelerated mortality in the SCD population.
The goal of this session is to present the spectrum of acute and chronic
pulmonary complications of SCD that impact patients across the lifespan to
actively engage pediatric and adult clinicians and researchers with the goals of
improved coordination of scientific efforts and implementation of state of the art
clinical care for patients.
Chairing: E.S. Klings, MD, Boston, MA
S.C. Sadreameli, MD, MHS, Baltimore, MD
M.T. Gladwin, MD, Pittsburgh, PA
9:00 A Patient’s Perspective
T. Pruitt, Oakland, CA
9:05 Unanswered Questions in the Pathophysiology of Sickle Cell
Lung Disease in Pediatric and Adult Care
E.S. Klings, MD, Boston, MA
9:25 Global Health Care Equality in Sickle Cell Disease
A.P. Ruhl, MD, MHS, Bethesda, MD
9:40 Night and Day: Intermittent Hypoxia in SCD
J.L. Allen, MD, Philadelphia, PA
10:00 How Should We Characterize Airway Disease in Sickle Cell
Patients?
R.T. Cohen, MD, MPH, Boston, MA
10:20 State of the Art Management of the Acute Chest Syndrome
J. Howard, MD, London, United Kingdom
10:40 Thrombosis, Hypoxia, and Hemolysis as Modulators of
Pulmonary Vascular Dysfunction in Sickle Cell Disease
R.F. Machado, MD, Chicago, IL
B10
There will be a 5-minute discussion after each talk.
BASIC • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
NEW CONCEPTS IN ASTHMA BIOLOGY
Assemblies on Respiratory Structure and Function; Allergy, Immunology
and Inflammation; Respiratory Cell and Molecular Biology
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2005/2007 (West Building, Level 2)
Target Audience
Basic scientists and clinicians interested in emerging concepts in asthma
pathobiology.
Objectives
At the conclusion of this session, the participant will be able to:
• appreciate newly discovered facets of the asthma phenotype;
• learn about asthma mechanisms that may be independent of type 2
inflammation;
• identify new experimental methods to assess function and dysfunction of
structural cells of the airway.
Type 2 inflammation occurs in many asthma patients, but not all, and has
shaped much of current thinking. Nevertheless, origins of the disease remain
unclear. This symposium is designed to consider new thinking in asthma
pathobiology, key structural cells of the airway, and unrecognized mechanisms
of disease that may be independent of type 2 inflammation.
Chairing: J.J. Fredberg, PhD, Boston, MA
R. Krishnan, PhD, Boston, MA
9:00 A Patient’s Perspective
K. Przywara , Mountain View, CA
9:05 Inflammation in Asthma: Cause or Modulator?
J.V. Fahy, MD, San Francisco, CA
MONDAY MORNING
ATS 2016 • San Francisco